3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Carcinoma, Non-Small-Cell Lung
71
Squamous Cell Carcinoma of Head and Neck
33
Parkinson Disease 4, Autosomal Dominant Lewy Body
31
Lung Neoplasms
28
Melanoma
23
Triple Negative Breast Neoplasms
22
Neoplasm Metastasis
20
Neoplasms
19
Colorectal Neoplasms
18
Breast Neoplasms
18
Endometrial Neoplasms
16
Ovarian Neoplasms
14
Head and Neck Neoplasms
14
Carcinoma, Renal Cell
12
Urinary Bladder Neoplasms
11
Carcinoma, Transitional Cell
10
Pancreatic Neoplasms
7
Esophageal Neoplasms
7
Carcinoma
7
Uterine Cervical Neoplasms
6
Sarcoma
6
Recurrence
6
Lymphoma
6
Hodgkin Disease
6
Stomach Neoplasms
4
Small Cell Lung Carcinoma
4
Prostatic Neoplasms
4
Multiple Myeloma
4
Mouth Neoplasms
4
Lymphoma, Large B-Cell, Diffuse
4
Interventions
pembrolizumab
2
enfortumab vedotin
2
Gemcitabine
2
testosterone 17 beta-cypionate
1
temsirolimus
1
Valproic Acid
1
Testosterone Propionate
1
Standard of Care
1
Sirolimus
1
Radiation Dose Hypofractionation
1
Practice Guidelines as Topic
1
Mitomycin
1
Methyltestosterone
1
Immunoglobulin G
1
Fluorouracil
1
Disulfides
1
Cisplatin
1
Cetuximab
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Urologic Neoplasms
×
pembrolizumab
×
30 days
×
Clear all
NCT05614739
2026-05-19
FORAGER-1
Eli Lilly and Company
Phase 1
Recruiting
535 enrolled
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled